Imatinib is known to be effective in the first-line treatment of metastatic gastrointestinal stromal tumours. A randomised, placebo-controlled trial has now shown that imatinib is safe and improves recurrence-free survival when used as adjuvant therapy after surgical resection of a primary gastrointestinal stromal tumour.
Leave a Reply